semaglutide 2.4 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Trial designs for SUSTAIN 2-4

2.4% placebo SURMOUNT-1 weight loss / up to 22.5% mean reduction at 72 weeks with tirzepatide 15 mg HbA1c in normoglycemic participants / dropped 0.2 to 0.5 percentage points in major GLP-1 trials SELECT cardiovascular benefit / 20% reduction in MACE with semaglutide 2.4 mg over 3.4 years median follow-up SCALE Obesity and Prediabetes / liraglutide 3.0 mg reduced new-onset type 2 diabetes by 79% over 3 years in prediabetic participants Fasting insulin reduction / 20 to 40% decreases observed across STEP and SURMOUNT programs Current ADA guidance / pharmacotherapy recommended as adjunct to lifestyle for adults with obesity What "Before Prediabetes" Actually Means A person can carry significant metabolic risk without meeting the laboratory cutoffs for prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4%)

Zepbound is specifically formulated for weight loss and has quickly become a favorite option for those looking for maximum results

Although the body can synthesise L-carnitine, we can also obtain it from certain foods

The keratin index values were significantly lower at GSSG sites than at placebo sites from Weeks 6 to 10 (Figure 3C)

The findings from these studies and others will provide critical evidence on the optimization of timing, dosing, and safety, as well as greater insights into target populations for maximum benefit in prevention and treatment of AD

This breaks the vacuum seal, making it easier to withdraw the medication